Samira Ghorbani Gazar; Alireza Andalib; Mohammad Hashemi; Abbas Rezaei
Volume 9, Issue 1 , March 2012, , Pages 53-60
Abstract
Background: Atherosclerosis is a multifactorial disorder with chronic inflammatory conditions in which immune cells play a significant role in its pathogenic process. Regulatory T cells (Treg), as a part of immune system, are involved in controlling autoimmune and inflammatory diseases. Quantitative ...
Read More
Background: Atherosclerosis is a multifactorial disorder with chronic inflammatory conditions in which immune cells play a significant role in its pathogenic process. Regulatory T cells (Treg), as a part of immune system, are involved in controlling autoimmune and inflammatory diseases. Quantitative and/or functional alteration of Tregs has been shown to play an atheroprotective role and may also promote plaque stabilization. Objective: To assess if inducible costimulatory molecule (ICOS) expression on one subtype of Treg cells with high suppressive potential correlates with the pathogenesis of atherosclerosis. Methods: Patients with myocardial infarction (MI) and/or stable angina (SA), diagnosed as atherosclerosis by angiography, and a group of individuals with normal coronary angiography (NCA) were recruited for the present study. Peripheral blood mononuclear cells (PBMCs) were prepared and the expression of ICOS, Foxp3 and CD4 molecules was tested by flowcytometry. Results: The percentage of CD4+Foxp3+ Treg cells was reduced in MI group compared to NCA and SA groups (p<0.005). Evaluation of the two Treg subsets according to ICOS expression showed a decreased ICOS+/ICOS- Treg ratio in MI and SA groups compared to NCA individuals (p=0.002 and p=0.048, respectively). Conclusion: The present data indicate that Tregs and its ICOS+ subsets are decreased in patients with MI or SA, suggesting a potential role for Treg in atherosclerosis progression or onset of acute coronary syndrome.
Abdollah Jafarzadeh; Masoud Poorgholami; Maryam Nemati; Mohammad-Taghi Rezayati
Volume 8, Issue 1 , March 2011, , Pages 34-44
Abstract
Background: Immunopathological and inflammatory processes play important roles in the initiation and development of Ischemic Heart Disease (IHD). Objective: The aim of this study was to evaluate the serum levels of several autoantibodies including rheumatoid factor (RF), anti-nuclear antibodies (ANA), ...
Read More
Background: Immunopathological and inflammatory processes play important roles in the initiation and development of Ischemic Heart Disease (IHD). Objective: The aim of this study was to evaluate the serum levels of several autoantibodies including rheumatoid factor (RF), anti-nuclear antibodies (ANA), anti-small nuclear ribonucleoprotein (anti-Sm), anti-phosphatidylserine (anti-PS) and anti-cardiolipin (anti-CL) antibodies in patients with IHD. Methods: A total of 120 patients with IHD with acute myocardial infarction (AMI; n=60) or unstable angina (UA; n=60) and 60 sex- and age-matched healthy subjects were enrolled in this study. Serum samples of participants were tested for the ANA, anti-Sm, anti-PS and anti-CL antibodies by ELISA. Serum level of RF was measured by a turbidometric method. Results: The mean serum levels of RF and anti-PS antibodies in AMI group and UA group were significantly higher than those observed in the control group (p<0.0001). The mean serum levels of RF and anti-PS antibodies in AMI patients were significantly higher than the UA group (p<0.01 and p<0.001, respectively). The mean serum levels of RF in men with AMI or UA diseases were significantly higher as compared to healthy control men (p<0.0001 and p<0.003, respectively). The differences of the serum levels of ANA, anti-Sm and anti-CL antibodies were not significant between AMI, UA and the control groups. There was no difference in the serum levels of RF, ANA, anti-Sm, anti-PS or anti-CL antibodies in patients with traditional risk factors, including hypertension, dyslipidemia, diabetes and smoking, and those without a certain risk factor. Conclusion: Higher serum levels of RF and anti-PS antibody in patients with IHD may be considered as independent risk factors for IHD.
Hasan Shemirani; Abbas Rezaei
Volume 3, Issue 2 , June 2006, , Pages 66-69
Abstract
Background: Myocardial infarction (MI) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. Streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following MI in most countries ...
Read More
Background: Myocardial infarction (MI) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. Streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following MI in most countries including Iran. Our previous study showed that, the prevalence of high antibody titers against streptokinase was 13.5% in the studied population from Iran, which was 2.5 times more common than data from other studies. Objective: To evaluate anti-streptokinase antibody titers before and immediately after streptokinase administration and its relation to reperfusion therapy success rates. Methods: A total of 200 patients with acute MI was selected. Antibodies against streptokinase were measured before and 2 days after administration of streptokinase. Before streptokinase administration and every hour after streptokinase administration, for 3 consecutive hours, an ECG was taken from each participant and changes were evaluated in relation to antibody levels. Results: Out of 200 patients, 42 (21%) had high levels of antibody titer. Out of these 42 patients, 13 (6.5%) still had measurable levels of anti-streptokinase antibody after streptokinase administration. Conclusion: Our results show the ability of the antistreptokinase antibody to neutralize the effects of streptokinase.